Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also provides non-diagnostic laboratory services and coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.
Australian Market Performance
7D7 Days: -0.2%
3M3 Months: 5.6%
1Y1 Year: 8.6%
YTDYear to Date: 5.1%
Over the last 7 days, the market has remained flat, although notably the Materials sector declined by 4.2%. As for the longer term, the market has risen 8.6% in the past 12 months. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.